arsenic trioxide has been researched along with Disease Models, Animal in 72 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (5.56) | 18.2507 |
| 2000's | 16 (22.22) | 29.6817 |
| 2010's | 40 (55.56) | 24.3611 |
| 2020's | 12 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Chu, L; Chu, X; Han, X; Li, L; Wu, Y; Wu, Z; Xue, Y; Zhang, J; Zhang, M; Zhao, Y; Zheng, B | 1 |
| Lang, X; Li, W; Luo, L; Ma, Y; Niu, S; Zhang, J; Zhang, Z; Zhao, Y; Zhu, X | 1 |
| Aitbayev, C; Batyrbekov, K; Begimbetova, D; Burska, AN; Fazyl, F; Gulyayev, A; Khamijan, M; Kukanova, A; Makishev, A; Manekenova, K; Omarov, T; Saliev, T; Sarbassov, D; Spatayev, Z; Yermekbayeva, B | 1 |
| Allanore, Y; Avouac, J; Cauvet, A; Decellas, A; Guignabert, C; Ottaviani, M; Rieger, F; Rongvaux-Gaïda, D; Thuillet, R; Tu, L | 1 |
| Bai, L; Fu, J; Li, M; Lu, J; Sun, Z; Wu, M; Wu, Y; Zhang, Y; Zhou, C | 1 |
| Chakraborty, S; Mondal, A; Saha, S; Samanta, J; Sengupta, A | 1 |
| Chen, J; Du, D; Liu, C; Wu, Y | 1 |
| Cheng, J; Chu, L; Guan, S; Han, X; Jin, W; Li, Z; Song, Q; Sun, S; Xue, Y; Zhang, J | 1 |
| Han, BR; Park, HK; Park, WH | 1 |
| Bhaumik, M; Chakraborty, M | 1 |
| Chu, L; Chu, X; Han, X; Li, M; Liang, Y; Liu, P; Shi, J; Xue, Y; Zhang, J | 1 |
| Cassinat, B; Dagher, T; de Thé, H; Edmond, V; Giraudier, S; Kiladjian, JJ; Lallemand-Breitenbach, V; Maslah, N; Niwa-Kawakita, M; Pasquier, F; Plo, I; Vainchenker, W; Verger, E; Villeval, JL | 1 |
| Chu, L; Chu, X; Guan, S; Han, X; He, Q; Sun, X; Wang, X; Wu, Y; Wu, Z; Zhang, J; Zhang, M; Zhao, Y | 1 |
| Bianchi, E; Bockstaller, M; Chan, JA; Chavez, L; Dorostkar, MM; Glass, R; Kool, M; Korshunov, A; Lambo, S; Meister, V; Merk, DJ; Neumann, JE; Neumann, P; Nowak, J; Renner-Müller, I; Schindler, P; Schneider, MR; Schüller, U; Shakarami, M; Sharma, T; Taketo, MM; von Hoff, K; Warmuth-Metz, M; Wefers, AK | 1 |
| Bi, Y; Chen, H; Fang, S; Hu, S; Kou, J; Li, T; Ma, R; Mo, H; Novakovic, VA; Shi, J; Wang, J; Wang, L; Yang, X; Yu, B; Zhang, Y; Zhou, J | 1 |
| Chen, D; Fu, X; Hao, H; He, W; Hou, Q; Li, M; Sun, M; Sun, S; Zhong, L; Zhu, Z | 1 |
| Cai, J; Chen, F; Lang, W; Zhong, J; Zhu, J | 1 |
| Du, Y; Sun, G; Sun, X; Wang, M; Wang, R; Wang, S; Xie, X; Ye, J; Ye, T; Zhang, J | 1 |
| Aster, JC; Avigan, D; Bhasin, MK; Cheloni, G; Chen, M; Clohessy, JG; Galinsky, I; Guarnerio, J; Lane, AA; Lee, JD; Lo-Coco, F; Longo, L; Mendez, L; Menon, AV; Monteleone, E; Mugoni, V; Pandolfi, PP; Panella, R; Pozdnyakova, O; Stone, RM; Stroopinsky, D; Zamora, JC | 1 |
| Hu, X; Li, L; Li, Z; Yan, S | 1 |
| Baek, SY; Kim, EY; Kim, SH; Lee, SS; Shin, DH; Shin, JH | 1 |
| Chen, P; Gong, S; Ji, X; Li, J; Li, K; Liu, S; Liu, Y; Ma, L; Wang, G; Xiang, X; Xu, L; Zeng, H; Zhang, L | 1 |
| Flemington, EK; Lasky, JA; Lin, Z; Luo, F; Sides, MD; Sosulski, ML | 1 |
| Chan, TC; Chang, WR; Chiou, SH; Fang, KM; Lin, TC; Liu, JJ; Ma, SZ; Tzeng, SF; Tzou, BC; Yang, CS | 1 |
| Fong, BM; Ho, JC; Lam, SK; Li, YY; Mak, JC; Zheng, CY | 1 |
| Brandt-Rauf, P; Cassai, N; Dinnen, RD; Fine, RL; Mao, Y; Nichols, G; Qiu, W; Slavkovich, VN; Su, GH | 1 |
| Foley, SB; Hildenbrand, ZL; Mgbemena, VE; Oravecz-Wilson, KI; Philips, ST; Ross, TS | 1 |
| Ao, JY; Bu, Y; Chai, ZT; Kong, LQ; Lu, L; Sun, HC; Tang, ZY; Zhang, KZ; Zhang, QB; Zhang, YY; Zhu, XD | 1 |
| Chen, YR; Dou, MM; Li, PC; Yang, S; Zhang, J; Zhao, XY | 1 |
| Hasan, SK; Lo-Coco, F | 1 |
| Chen, XF; Han, DY; Sun, QX; Zhao, HB; Zhao, SG | 1 |
| Li, Q; Li, Y; Liu, H; Liu, R; Shen, X; Wang, W; Yu, G | 1 |
| Cheng, P; Gao, C; Jiang, J; Jin, N; Leng, Y; Li, C; Li, J; Li, Q; Lian, Y; Lin, Y; Ma, P; Peng, Y; Qi, Z; Wang, F; Wang, L; Xia, J; Zhao, B | 1 |
| Bernardi, R; Coltella, N; Ponente, M; Ponzoni, M; Valsecchi, R | 1 |
| Chan, R; Feddock, JM; Jyoti, A; Langner, UW; Nagarajan, R; O'Halloran, TV; Sethi, P; Swindell, EP; Upreti, M | 1 |
| Chen, SJ; Cui, W; Fei, AM; Gressin, R; Hermine, O; Khochbin, S; Liu, YF; Mi, JQ; Miao, SC; Peng, LJ; Wang, J; Zhao, LL | 1 |
| Matsushita, H | 1 |
| Adès, L; Alex, AA; Chomienne, C; Fenaux, P; Ganesan, S; Gorombei, P; Guerenne, L; Krief, P; Mathews, V; Omidvar, N; Padua, RA; Patel, S; Pla, M; Schlageter, MH; West, R | 1 |
| Bott, AJ; Catanzaro, JM; Chen, JS; Diaz-Meco, MT; Ding, WX; Dou, Z; Du, C; Jaber, N; Jiang, YP; Lin, RZ; Moscat, J; Ozato, K; Pan, JA; Sun, Y; Yang, B; Zong, WX | 1 |
| Hao, L; Lu-Qun, W; Ran, W; Xiang-Xin, L; Xiao-Ning, Y | 1 |
| Fan, L; Feng, H; Jia, B; Lan, F; Li, L; Liu, Q; Wang, T; Wang, Y; Xiao, W; Xing, G; Ye, W; Yue, X; Zhao, L; Zhou, C | 1 |
| He, X; Huang, H; Liu, W; Wang, J; Wei, Z; Yang, Z; Zhang, J; Zhang, Y | 1 |
| Bobé, P; Chelbi-Alix, MK | 1 |
| Chang, H; Chen, G; Feng, Y; Huang, H; Lin, F; Sun, A; Wang, Y; Wu, D | 1 |
| Jiang, HC; Liu, TF; Song, PL; Sun, B; Zhao, XS | 1 |
| Cai, BC; Chiang, BL; Chu, KH; Hsin, SC; Lee, CC; Wang, JH | 1 |
| Ahn, RW; Chen, F; Chen, H; Clogston, JD; Cryns, VL; O'Halloran, TV; Parimi, V; Patri, AK; Raja, MR; Stern, ST; Swindell, EP | 1 |
| Chelbi-Alix, MK; Singer, M; Trugnan, G | 1 |
| Gao, J; Liu, D; Mei, Y; Wang, H; Zhang, Z; Zhao, Y; Zheng, Y | 1 |
| Abreu e Lima, RS; Curti, C; de Thé, H; dos Santos, GA; Falcão, RP; Gimenes-Teixeira, HL; Lima, AS; Lucena-Araujo, AR; Nasr, R; Pandolfi, PP; Pestana, CR; Rego, EM; Rodrigues, FP; Santana-Lemos, BA; Scheucher, PS; Thomé, CH; Uyemura, SA | 1 |
| Calderon, PB; Dauguet, N; Diepart, C; Feron, O; Gallez, B; Grégoire, V; Jordan, BF; Karroum, O; Leveque, P; Magat, J; Stockis, J; Verrax, J | 1 |
| Batteux, F; Chéreau, C; Kavian, N; Laude, H; Marut, W; Nicco, C; Servettaz, A; Weill, B | 1 |
| Batteux, F; Borderie, D; Chéreau, C; Dupin, N; Kavian, N; Lemaréchal, H; Marut, W; Nicco, C; Servettaz, A; Weill, B | 1 |
| Canet, MJ; Cherrington, NJ; Gandolfi, AJ; Hardwick, RN; Klimecki, WT; Kopplin, MJ; Lake, AD; Scheffer, GL | 1 |
| Bing Ma, L; Chen, P; Gong, SB; Ji, XY; Li, K; Liu, SK; Liu, Y; Ouyang, RY; Wang, GY; Xiang, XD; Xu, L; Zhang, L | 1 |
| Huang, SG; Jiang, S; Kong, BH; Yang, RF | 1 |
| Ahmed, M; Gazelle, GS; Goldberg, SN; Horkan, C; Kruskal, JB; Liu, Z; Solazzo, SA | 1 |
| Chow, J; Huang, M; Lee, C; Lin, C; Lin, Y; Liu, C; Liu, HE | 1 |
| Jin, J; Lu, J; Xu, WL | 1 |
| Goldberg, SN; Hines-Peralta, A; Liu, ZJ; Regan, M; Signoretti, S; Sukhatme, V | 1 |
| Jin, J; Lu, J | 1 |
| Jin, W; Sun, BG; Wen, QZ; Xue, JX; Zhang, JJ; Zhao, JL; Zhuang, WY | 1 |
| Banerjee, P; Belon, P; Biswas, SJ; Khuda-Bukhsh, AR | 1 |
| Chen, SJ; Chen, Z; Li, G; Zhou, GB | 1 |
| Cai, YX; Fu, YB; Li, L; Meng, FY; Sun, QX | 1 |
| Delos, M; Lardot, C; Lasfargues, G; Lauwerys, R; Lison, D | 1 |
| Bukhsh, AR; Datta, S; Mallick, P | 2 |
| Brown, SL; Griffin, RJ; Kim, JH; Lew, YS; Song, CW | 1 |
| Calleja, EM; Warrell, RP | 1 |
| Chen, GQ; Chen, SJ; Chen, Z; Wang, ZG; Wang, ZY; Zhang, TD | 1 |
| Liang, X; Lin, C; Xu, M | 1 |
5 review(s) available for arsenic trioxide and Disease Models, Animal
| Article | Year |
|---|---|
Understanding the molecular pathogenesis of acute promyelocytic leukemia.
Topics: Animals; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cell Differentiation; Cell Transformation, Neoplastic; Chromosomes, Human, Pair 15; Chromosomes, Human, Pair 17; Clinical Trials as Topic; Disease Models, Animal; DNA End-Joining Repair; Drug Synergism; Granulocyte Precursor Cells; Humans; Leukemia, Promyelocytic, Acute; Mice; Molecular Targeted Therapy; Neoplasm Proteins; Neoplasms, Second Primary; Neoplastic Stem Cells; Oncogene Proteins, Fusion; Oxides; Signal Transduction; Topoisomerase II Inhibitors; Translocation, Genetic; Tretinoin | 2014 |
[Pathogenesis of Acute Promyelocytic Leukemia].
Topics: Animals; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Disease Models, Animal; Epigenomics; Humans; Leukemia, Promyelocytic, Acute; Medicine, Chinese Traditional; Mice; Molecular Targeted Therapy; Oncogene Proteins, Fusion; Oxides; Transcription, Genetic; Tretinoin | 2015 |
From dissection of disease pathogenesis to elucidation of mechanisms of targeted therapies: leukemia research in the genomic era.
Topics: Animals; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Benzamides; Disease Models, Animal; Humans; Imatinib Mesylate; Leukemia; Oxides; Piperazines; Pyrimidines; Tretinoin | 2007 |
Differentiating agents in pediatric malignancies: all-trans-retinoic acid and arsenic in acute promyelocytic leukemia.
Topics: Animals; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cell Differentiation; Child; Disease Models, Animal; Drug Therapy, Combination; Humans; Leukemia, Promyelocytic, Acute; Oxides; Tretinoin | 2000 |
Arsenic trioxide, a therapeutic agent for APL.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Differentiation; Disease Models, Animal; Drug Synergism; Humans; Leukemia, Promyelocytic, Acute; Mice; Mitochondria; Neoplasm Proteins; Nuclear Proteins; Oncogene Proteins, Fusion; Oxides; Promyelocytic Leukemia Protein; Remission Induction; Survival Rate; Transcription Factors; Tretinoin; Tumor Suppressor Proteins | 2001 |
67 other study(ies) available for arsenic trioxide and Disease Models, Animal
| Article | Year |
|---|---|
Liquiritigenin protects against arsenic trioxide-induced liver injury by inhibiting oxidative stress and enhancing mTOR-mediated autophagy.
Topics: Animals; Antioxidants; Arsenic Trioxide; Autophagy; Chemical and Drug Induced Liver Injury; Disease Models, Animal; Flavanones; Liver; Male; Mice; Oxidative Stress; Phosphatidylinositol 3-Kinase; Proto-Oncogene Proteins c-akt; Signal Transduction; TOR Serine-Threonine Kinases | 2021 |
Arsenic trioxide modulates the composition and metabolic function of the gut microbiota in a mouse model of rheumatoid arthritis.
Topics: Animals; Arsenic Trioxide; Arthritis, Experimental; Arthritis, Rheumatoid; Disease Models, Animal; Feces; Gastrointestinal Microbiome; Mice | 2022 |
The Oxidative Drug Combination for Suppressing KRAS G12D Inducible Tumour Growth.
Topics: Animals; Arsenic Trioxide; Ascorbic Acid; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Disease Models, Animal; Drug Combinations; Humans; Mice; Oxidation-Reduction; Oxidative Stress; Pancreatic Neoplasms; Proto-Oncogene Proteins p21(ras) | 2022 |
Arsenic trioxide demonstrates efficacy in a mouse model of preclinical systemic sclerosis.
Topics: Animals; Arsenic Trioxide; Disease Models, Animal; Humans; Mice; Scleroderma, Localized; Scleroderma, Systemic; Vascular Remodeling | 2023 |
Arsenic trioxide inhibits angiogenesis in vitro and in vivo by upregulating FoxO3a.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Arsenic Trioxide; Cell Enlargement; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; Epithelial Cells; Forkhead Box Protein O3; Gene Expression Regulation, Neoplastic; Humans; Leukemia, Promyelocytic, Acute; Mice; Umbilical Veins; Up-Regulation | 2019 |
Oleic Acid Protects from Arsenic-Induced Cardiac Hypertrophy via AMPK/FoxO/NFATc3 Pathway.
Topics: AMP-Activated Protein Kinases; Animals; Arsenic Trioxide; Cardiomegaly; Cardiotoxicity; Cell Line; Disease Models, Animal; Fibrosis; Forkhead Box Protein O1; Male; Mice; Myocytes, Cardiac; Nerve Tissue Proteins; NFATC Transcription Factors; Oleic Acid; Signal Transduction | 2020 |
Preparation of PLGA microspheres loaded with 10-hydroxycamptothecin and arsenic trioxide and their treatment for rabbit hepatocellular carcinoma.
Topics: Animals; Antineoplastic Agents; Arsenic Trioxide; Camptothecin; Carcinoma, Hepatocellular; Disease Models, Animal; Liver Neoplasms; Microspheres; Polylactic Acid-Polyglycolic Acid Copolymer; Rabbits | 2021 |
Tannic acid ameliorates arsenic trioxide-induced nephrotoxicity, contribution of NF-κB and Nrf2 pathways.
Topics: Animals; Antioxidants; Apoptosis; Arsenic Trioxide; Disease Models, Animal; Inflammation; Interleukins; Kidney; Kidney Diseases; Male; NF-E2-Related Factor 2; NF-kappa B; Oxidative Stress; Rats; Tannins | 2020 |
Combination of Arsenic Trioxide and Valproic Acid Efficiently Inhibits Growth of Lung Cancer Cells via G2/M-Phase Arrest and Apoptotic Cell Death.
Topics: Animals; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Biomarkers; Cell Line, Tumor; Disease Models, Animal; Drug Synergism; G2 Phase Cell Cycle Checkpoints; Humans; Lung Neoplasms; Membrane Potential, Mitochondrial; Mice; Valproic Acid; Xenograft Model Antitumor Assays | 2020 |
Prenatal arsenic exposure interferes in postnatal immunocompetence despite an absence of ongoing arsenic exposure.
Topics: Animals; Animals, Newborn; Antigens, CD; Antigens, Differentiation, T-Lymphocyte; Arsenic Trioxide; CD8-Positive T-Lymphocytes; Disease Models, Animal; Disease Susceptibility; Escherichia coli; Escherichia coli Infections; Female; Humans; Hyaluronan Receptors; Interferon-gamma; Interleukin-2; Lectins, C-Type; Male; Maternal Exposure; Maternal-Fetal Exchange; Mice; Placental Circulation; Pregnancy; Prenatal Exposure Delayed Effects | 2020 |
Tannic acid attenuates hepatic oxidative stress, apoptosis and inflammation by activating the Keap1‑Nrf2/ARE signaling pathway in arsenic trioxide‑toxicated rats.
Topics: Animals; Antioxidant Response Elements; Apoptosis; Arsenic Trioxide; Chemical and Drug Induced Liver Injury; Disease Models, Animal; Humans; Inflammation; Injections, Intraperitoneal; Kelch-Like ECH-Associated Protein 1; Liver; Liver Function Tests; Male; NF-E2-Related Factor 2; Oxidative Stress; Rats; Signal Transduction; Tannins | 2020 |
JAK2V617F myeloproliferative neoplasm eradication by a novel interferon/arsenic therapy involves PML.
Topics: Animals; Arsenic Trioxide; Cell Line; Cell Line, Tumor; Disease Models, Animal; Humans; Interferon-alpha; Janus Kinase 2; Leukemia, Promyelocytic, Acute; Mice; Mice, Inbred C57BL; Mice, Transgenic; Myeloproliferative Disorders; Promyelocytic Leukemia Protein | 2021 |
Investigation of the ameliorative effects of baicalin against arsenic trioxide-induced cardiac toxicity in mice.
Topics: Animals; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Cardiotoxicity; Disease Models, Animal; Flavonoids; Humans; Inflammation; Male; Mice; NF-kappa B; Oxidative Stress; Scutellaria; Signal Transduction; Toll-Like Receptor 4 | 2021 |
A mouse model for embryonal tumors with multilayered rosettes uncovers the therapeutic potential of Sonic-hedgehog inhibitors.
Topics: Animals; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Blotting, Western; Brain Neoplasms; Cell Line, Tumor; Disease Models, Animal; Down-Regulation; Gene Expression Profiling; Hedgehog Proteins; Humans; Immunohistochemistry; Mice; Mice, Transgenic; MicroRNAs; Neoplasms, Germ Cell and Embryonal; Oxides; Reverse Transcriptase Polymerase Chain Reaction; RNA-Binding Proteins; Signal Transduction; Wnt Signaling Pathway; Xenograft Model Antitumor Assays; Zinc Finger Protein GLI1 | 2017 |
Arsenic trioxide promoting ETosis in acute promyelocytic leukemia through mTOR-regulated autophagy.
Topics: Adolescent; Adult; Animals; Apoptosis; Arsenic Trioxide; Autophagy; Cell Line, Tumor; Disease Models, Animal; Drug Synergism; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Mice, SCID; Middle Aged; Neoplasm Recurrence, Local; Neoplastic Stem Cells; Reactive Oxygen Species; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases; Tumor Burden; Young Adult | 2018 |
Arsenic trioxide inhibits the differentiation of fibroblasts to myofibroblasts through nuclear factor erythroid 2-like 2 (NFE2L2) protein and the Smad2/3 pathway.
Topics: Animals; Arsenic Trioxide; Cell Differentiation; Disease Models, Animal; Extracellular Matrix; Fibroblasts; Humans; Myofibroblasts; NF-E2-Related Factor 2; Rabbits; Signal Transduction; Skin; Smad2 Protein; Smad3 Protein | 2019 |
EVI-1 modulates arsenic trioxide induced apoptosis through JNK signalling pathway in leukemia cells.
Topics: Animals; Anthracenes; Apoptosis; Arsenic Trioxide; Cell Line, Tumor; Disease Models, Animal; Down-Regulation; Gene Expression Regulation, Leukemic; Humans; Leukemia; MAP Kinase Signaling System; MDS1 and EVI1 Complex Locus Protein; Models, Biological; Neoplasm Proteins; RNA, Messenger; Zebrafish | 2019 |
The Cardiotoxicity Induced by Arsenic Trioxide is Alleviated by Salvianolic Acid A via Maintaining Calcium Homeostasis and Inhibiting Endoplasmic Reticulum Stress.
Topics: Animals; Apoptosis; Arsenic Trioxide; Caffeic Acids; Calcium; Cardiotoxicity; Disease Models, Animal; Endoplasmic Reticulum Stress; Gene Expression Regulation; Homeostasis; Humans; Lactates; Leukemia, Promyelocytic, Acute; Mice; Myocytes, Cardiac; Rats; Sarcoplasmic Reticulum; Sarcoplasmic Reticulum Calcium-Transporting ATPases | 2019 |
Vulnerabilities in mIDH2 AML confer sensitivity to APL-like targeted combination therapy.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Disease Models, Animal; Humans; Isocitrate Dehydrogenase; Leukemia, Myeloid, Acute; Leukemia, Promyelocytic, Acute; Mice; Mice, Inbred C57BL; Mice, Transgenic; Mutation; Neoplasms, Experimental; Tretinoin; Tumor Cells, Cultured; U937 Cells | 2019 |
Arsenic trioxide suppresses acute graft-versus-host disease by activating the Nrf2/HO-1 pathway in mice.
Topics: Animals; Antineoplastic Agents; Arsenic Trioxide; Disease Models, Animal; Graft vs Host Disease; Heme Oxygenase-1; Mice; NF-E2-Related Factor 2 | 2019 |
Anticancer effect of arsenic trioxide on cholangiocarcinoma: in vitro experiments and in vivo xenograft mouse model.
Topics: Animals; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cholangiocarcinoma; Disease Models, Animal; Heterografts; Humans; Mice, Inbred BALB C; Mice, Nude; Oxides; Staining and Labeling; Tetrazolium Salts; Thiazoles; Treatment Outcome | 2014 |
Arsenic trioxide alleviates airway hyperresponsiveness and promotes apoptosis of CD4+ T lymphocytes: evidence for involvement of the ER stress-CHOP pathway.
Topics: Animals; Anti-Asthmatic Agents; Anti-Inflammatory Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Asthma; Bronchial Hyperreactivity; Bronchoalveolar Lavage Fluid; Bronchoconstriction; CD4-Positive T-Lymphocytes; Cells, Cultured; Disease Models, Animal; Endoplasmic Reticulum Chaperone BiP; Endoplasmic Reticulum Stress; Female; Heat-Shock Proteins; Lung; Mice; Mice, Inbred BALB C; Oxides; RNA Interference; Signal Transduction; Transcription Factor CHOP; Transfection | 2013 |
Co-treatment with arsenic trioxide and ganciclovir reduces tumor volume in a murine xenograft model of nasopharyngeal carcinoma.
Topics: Animals; Antineoplastic Agents; Antiviral Agents; Arsenic Trioxide; Arsenicals; Carcinoma; Disease Models, Animal; Drug Therapy, Combination; Ganciclovir; Heterografts; Humans; Mice; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Oxides; Treatment Outcome; Tumor Burden | 2013 |
Enhanced cell growth and tumorigenicity of rat glioma cells by stable expression of human CD133 through multiple molecular actions.
Topics: AC133 Antigen; Animals; Antigens, CD; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Basic Helix-Loop-Helix Transcription Factors; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Transformation, Neoplastic; Cerebral Cortex; Disease Models, Animal; Dose-Response Relationship, Drug; Enzyme Inhibitors; Female; Formazans; Gene Expression Regulation, Neoplastic; Glioma; Glycoproteins; GTPase-Activating Proteins; Homeodomain Proteins; Humans; Intercellular Signaling Peptides and Proteins; Lentivirus; Oncogene Protein v-akt; Oxides; Peptides; Rats; Rats, Sprague-Dawley; Receptor, Notch1; RNA, Messenger; RNA, Small Interfering; Tetrazolium Salts; Time Factors; Transcription Factor HES-1; Transfection; Tumor Stem Cell Assay | 2013 |
Combination of arsenic trioxide and chemotherapy in small cell lung cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Cell Proliferation; Cisplatin; Disease Models, Animal; DNA Damage; Drug Synergism; Etoposide; Female; Glutathione; Humans; Lung Neoplasms; Membrane Potential, Mitochondrial; Mice; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Oxides; Reactive Oxygen Species; Small Cell Lung Carcinoma; Xenograft Model Antitumor Assays | 2013 |
Redirecting apoptosis to aponecrosis induces selective cytotoxicity to pancreatic cancer cells through increased ROS, decline in ATP levels, and VDAC.
Topics: Adenosine Triphosphate; Animals; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Ascorbic Acid; Cell Line, Tumor; Disease Models, Animal; Disulfiram; Dose-Response Relationship, Drug; Heterografts; Humans; Male; Mice; Necrosis; Oxides; Pancreatic Neoplasms; Reactive Oxygen Species; Tumor Stem Cell Assay; Voltage-Dependent Anion Channels | 2013 |
Toward a therapeutic reduction of imatinib refractory myeloproliferative neoplasm-initiating cells.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Benzamides; Blotting, Western; Bone Marrow Transplantation; Core Binding Factor Alpha 2 Subunit; Disease Models, Animal; DNA-Binding Proteins; Drug Resistance, Neoplasm; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cells; Humans; Imatinib Mesylate; Mice, Inbred C57BL; Mice, Transgenic; Myeloproliferative Disorders; Neoplasm Recurrence, Local; Neoplastic Stem Cells; Oligonucleotide Array Sequence Analysis; Oxides; Piperazines; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; Treatment Outcome | 2014 |
Arsenic trioxide induces differentiation of CD133+ hepatocellular carcinoma cells and prolongs posthepatectomy survival by targeting GLI1 expression in a mouse model.
Topics: AC133 Antigen; Animals; Antigens, CD; Arsenic Trioxide; Arsenicals; Carcinoma, Hepatocellular; Cell Differentiation; Cell Line, Tumor; Disease Models, Animal; Down-Regulation; Glycoproteins; Humans; Liver Neoplasms; Male; Mice; Mice, Inbred NOD; Mice, SCID; Neoplasm Recurrence, Local; Neoplastic Stem Cells; Oxides; Peptides; Random Allocation; Signal Transduction; Survival Analysis; Transcription Factors; Xenograft Model Antitumor Assays; Zinc Finger Protein GLI1 | 2014 |
Resveratrol and arsenic trioxide act synergistically to kill tumor cells in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Cell Proliferation; Cell Survival; Disease Models, Animal; Drug Synergism; Humans; Male; Mice; Necrosis; Neovascularization, Pathologic; Oxides; Reactive Oxygen Species; Resveratrol; Stilbenes; Tumor Burden; Xenograft Model Antitumor Assays | 2014 |
Efficacy of intratumoral chemotherapy using arsenic trioxide (As2O3) sustained release tablets for the treatment of neurogliocytoma in nude mice.
Topics: Animals; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Brain Neoplasms; Delayed-Action Preparations; Disease Models, Animal; Drug Carriers; Glioma; Injection, Intratympanic; Lactic Acid; Mice; Mice, Inbred BALB C; Mice, Nude; Oxides; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Random Allocation; Tablets | 2014 |
Construction of a BALB/c-Nu Mouse Model of Invasive Bladder Carcinoma and Preliminary Studies on the Treatment of Bladder Tumors through Internal Iliac Arterial Infusion of Albumin-Bound Arsenic Trioxide (As2O3).
Topics: Animals; Arsenic Trioxide; Arsenicals; Carcinoma; Cell Line, Tumor; Disease Models, Animal; Humans; Infusions, Intra-Arterial; Mice; Mice, Inbred BALB C; Oxides; Serum Albumin, Bovine; Urinary Bladder Neoplasms; Xenograft Model Antitumor Assays | 2015 |
Arsenic Trioxide Induces T Cell Apoptosis and Prolongs Islet Allograft Survival in Mice.
Topics: Animals; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Proliferation; Cells, Cultured; Disease Models, Animal; Dose-Response Relationship, Drug; Female; Graft Rejection; Graft Survival; I-kappa B Proteins; Immunity, Cellular; Immunosuppressive Agents; Islets of Langerhans; Islets of Langerhans Transplantation; Lymphocyte Activation; Mice, Inbred BALB C; Mice, Inbred C57BL; NF-KappaB Inhibitor alpha; Oxides; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Signal Transduction; T-Lymphocytes; Time Factors | 2015 |
Synergistic Leukemia Eradication by Combined Treatment with Retinoic Acid and HIF Inhibition by EZN-2208 (PEG-SN38) in Preclinical Models of PML-RARα and PLZF-RARα-Driven Leukemia.
Topics: Animals; Arsenic Trioxide; Arsenicals; Camptothecin; Cell Differentiation; Cell Movement; Disease Models, Animal; Drug Resistance, Neoplasm; Drug Synergism; Gene Expression Regulation, Neoplastic; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Leukemia, Promyelocytic, Acute; Mice; Mutation; Neoplasm Proteins; Oncogene Proteins, Fusion; Oxides; Polyethylene Glycols; Tretinoin | 2015 |
3D tumor tissue analogs and their orthotopic implants for understanding tumor-targeting of microenvironment-responsive nanosized chemotherapy and radiation.
Topics: Animals; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Breast; Cisplatin; Coculture Techniques; Disease Models, Animal; Drug Delivery Systems; Endothelial Cells; Female; Fibroblasts; Galectin 1; Mice; Mice, Nude; Nanoparticles; Oxides; Spheroids, Cellular; Triple Negative Breast Neoplasms; Tumor Cells, Cultured; Tumor Microenvironment | 2015 |
Arsenic trioxide rewires mantle cell lymphoma response to bortezomib.
Topics: Animals; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; bcl-2 Homologous Antagonist-Killer Protein; bcl-2-Associated X Protein; Bortezomib; Caspases; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; Drug Synergism; Female; Humans; Lymphoma, Mantle-Cell; Membrane Potential, Mitochondrial; Mice; Myeloid Cell Leukemia Sequence 1 Protein; Oxides; Protein Binding; Proto-Oncogene Proteins c-bcl-2; Xenograft Model Antitumor Assays | 2015 |
pVAX14DNA-mediated add-on immunotherapy combined with arsenic trioxide and all-trans retinoic acid targeted therapy effectively increases the survival of acute promyelocytic leukemia mice.
Topics: Adjuvants, Immunologic; Animals; Arsenic Trioxide; Arsenicals; Disease Models, Animal; DNA; Immunotherapy; Leukemia, Promyelocytic, Acute; Mice; Oxides; Tretinoin | 2015 |
TRIM21 Ubiquitylates SQSTM1/p62 and Suppresses Protein Sequestration to Regulate Redox Homeostasis.
Topics: Adaptor Proteins, Signal Transducing; Animals; Arsenic Trioxide; Arsenicals; Cell Death; Chemical and Drug Induced Liver Injury; Cytoskeletal Proteins; Disease Models, Animal; Heart Failure; Heat-Shock Proteins; HEK293 Cells; Homeostasis; Humans; Intracellular Signaling Peptides and Proteins; Kelch-Like ECH-Associated Protein 1; Liver; Lysine; Mice; Mice, Inbred C57BL; Mice, Knockout; Myocardium; Oxidation-Reduction; Oxidative Stress; Oxides; Protein Binding; Protein Interaction Domains and Motifs; Protein Multimerization; Ribonucleoproteins; RNA Interference; Sequestosome-1 Protein; Signal Transduction; Time Factors; Transfection; Ubiquitination | 2016 |
Carnosic Acid-combined Arsenic Trioxide Antileukaemia Cells in the Establishment of NB4/SCID Mouse Model.
Topics: Abietanes; Animals; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Caspase 3; Cell Line, Tumor; Disease Models, Animal; Drug Synergism; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Mice; Mice, SCID; Oxides; PTEN Phosphohydrolase; RNA, Messenger | 2016 |
Protective effects of oxymatrine against arsenic trioxide-induced liver injury.
Topics: Alkaloids; Animals; Antioxidants; Arsenic Trioxide; Arsenicals; Blotting, Western; Chemical and Drug Induced Liver Injury; Disease Models, Animal; Heme Oxygenase-1; Male; NF-E2-Related Factor 2; Oxidative Stress; Oxides; Quinolizines; Rats; Rats, Wistar; Signal Transduction | 2017 |
Melatonin protects against arsenic trioxide-induced liver injury by the upregulation of Nrf2 expression through the activation of PI3K/AKT pathway.
Topics: Animals; Arsenic Trioxide; Arsenicals; Chemical and Drug Induced Liver Injury; Disease Models, Animal; Gene Expression Regulation; Injections, Intraperitoneal; Liver; Male; Melatonin; NF-E2-Related Factor 2; Oxidative Stress; Oxides; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Rats; Signal Transduction; Up-Regulation | 2017 |
[New therapeutic perspectives for arsenic: from acute promyelocytic leukemia to autoimmune diseases].
Topics: Animals; Antineoplastic Agents; Arsenic; Arsenic Trioxide; Arsenicals; Autoimmune Diseases; Disease Models, Animal; Growth Inhibitors; Humans; Leukemia, Promyelocytic, Acute; Lupus Erythematosus, Systemic; Lymphoproliferative Disorders; Mice; Oxides | 2008 |
Combination of DNA methylation inhibitor 5-azacytidine and arsenic trioxide has synergistic activity in myeloma.
Topics: Adaptor Proteins, Signal Transducing; Animals; Apoptosis; Apoptosis Regulatory Proteins; Arsenic Trioxide; Arsenicals; Azacitidine; Base Sequence; Cell Line, Tumor; Disease Models, Animal; DNA Methylation; Drug Synergism; Female; Gene Expression Regulation, Neoplastic; Humans; Intracellular Signaling Peptides and Proteins; Leukemia, Myeloid; Mice; Mice, Inbred BALB C; Mice, Nude; Molecular Sequence Data; Neoplasm Proteins; Oxides; RNA, Messenger; Transcription, Genetic; Xenograft Model Antitumor Assays | 2009 |
Arsenic trioxide inhibits metastatic potential of mouse hepatoma H22 cells in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Carcinoma, Hepatocellular; Cell Adhesion; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Disease Models, Animal; Dose-Response Relationship, Drug; Liver Neoplasms; Lung Neoplasms; Male; Matrix Metalloproteinase 2; Mice; NM23 Nucleoside Diphosphate Kinases; Oxides; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 2009 |
Arsenic trioxide alleviates airway hyperresponsiveness and eosinophilia in a murine model of asthma.
Topics: Animals; Apoptosis; Arsenic Trioxide; Arsenicals; Asthma; Bronchial Hyperreactivity; Bronchoalveolar Lavage Fluid; Cells, Cultured; Disease Models, Animal; Eosinophils; Female; Immunoglobulin E; Interleukin-5; Mice; Mice, Inbred BALB C; Oxides | 2010 |
A novel nanoparticulate formulation of arsenic trioxide with enhanced therapeutic efficacy in a murine model of breast cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Breast Neoplasms; Cell Proliferation; Cell Survival; Disease Models, Animal; Female; Humans; Mammary Neoplasms, Experimental; Mice; Nanoparticles; Oxides; Rats; Rats, Sprague-Dawley; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2010 |
Arsenic trioxide reduces 2,4,6-trinitrobenzene sulfonic acid-induced murine colitis via nuclear factor-κB down-regulation and caspase-3 activation.
Topics: Animals; Anti-Inflammatory Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Caspase 3; Colitis; Colon; Crohn Disease; Cytokines; Disease Models, Animal; Humans; Male; Mice; Mice, Inbred BALB C; NF-kappa B; Nitric Oxide Synthase Type II; Oxides; Peroxidase; Trinitrobenzenesulfonic Acid | 2011 |
Arsenic trioxide induces apoptosis of fibroblast-like synoviocytes and represents antiarthritis effect in experimental model of rheumatoid arthritis.
Topics: Animals; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Arthritis, Experimental; Arthritis, Rheumatoid; Caspase 8; Cells, Cultured; Disease Models, Animal; Fibroblasts; Humans; In Situ Nick-End Labeling; NF-kappa B; Oxides; Rats; Synovial Membrane | 2011 |
(+)α-Tocopheryl succinate inhibits the mitochondrial respiratory chain complex I and is as effective as arsenic trioxide or ATRA against acute promyelocytic leukemia in vivo.
Topics: alpha-Tocopherol; Animals; Antineoplastic Agents; Antioxidants; Apoptosis; Arsenic Trioxide; Arsenicals; Caspases; Cell Line, Tumor; Cytochromes c; Disease Models, Animal; Electron Transport Complex I; Electron Transport Complex II; Humans; Leukemia, Promyelocytic, Acute; Membrane Potential, Mitochondrial; Mice; Mice, Transgenic; Mitochondria; Neoplastic Stem Cells; Oncogene Proteins, Fusion; Oxides; Protein Stability; Rats; Reactive Oxygen Species; Transplantation, Isogeneic; Tretinoin | 2012 |
Arsenic trioxide treatment decreases the oxygen consumption rate of tumor cells and radiosensitizes solid tumors.
Topics: Animals; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Carcinoma, Lewis Lung; Combined Modality Therapy; Disease Models, Animal; Liver Neoplasms, Experimental; Male; Mice; Mice, Inbred C57BL; Oxides; Oxygen Consumption; Radiation-Sensitizing Agents | 2012 |
Arsenic trioxide prevents murine sclerodermatous graft-versus-host disease.
Topics: Animals; Arsenic Trioxide; Arsenicals; Bone Marrow Transplantation; Chronic Disease; Disease Models, Animal; Female; Fibrosis; Graft vs Host Disease; Male; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Oxides; Random Allocation; Scleroderma, Systemic; Spleen | 2012 |
Reactive oxygen species-mediated killing of activated fibroblasts by arsenic trioxide ameliorates fibrosis in a murine model of systemic sclerosis.
Topics: Animals; Arsenic Trioxide; Arsenicals; Autoantibodies; Collagen; Disease Models, Animal; Fibroblasts; Fibrosis; Glutathione; Interleukin-13; Interleukin-4; Mice; Oxides; Reactive Oxygen Species; Scleroderma, Systemic; Skin; Vascular Cell Adhesion Molecule-1 | 2012 |
Altered arsenic disposition in experimental nonalcoholic fatty liver disease.
Topics: Animals; Arsenates; Arsenic Trioxide; Arsenicals; Biotransformation; Choline Deficiency; Diet, High-Fat; Disease Models, Animal; Environmental Pollutants; Fatty Liver; Kidney; Liver; Male; Methionine; Methyltransferases; Mice; Mice, Inbred C57BL; Multidrug Resistance-Associated Proteins; Non-alcoholic Fatty Liver Disease; Oxides | 2012 |
Effects and mechanism of arsenic trioxide on reversing the asthma pathologies including Th17-IL-17 axis in a mouse model.
Topics: Animals; Anti-Asthmatic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Asthma; Bronchial Hyperreactivity; Bronchial Provocation Tests; Calcium; Caspase 12; Cells, Cultured; Dexamethasone; Disease Models, Animal; Female; Interleukin-17; Lung; Membrane Potential, Mitochondrial; Mice; Mice, Inbred BALB C; Mucus; Ovalbumin; Oxides; Signal Transduction; Th17 Cells | 2012 |
[Primary study of arsenic trioxide inhibits abdomino-metastatic tumor formation of human ovarian carcinoma in nude mice and its mechanisms].
Topics: Animals; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Disease Models, Animal; Fas Ligand Protein; fas Receptor; Female; Humans; Membrane Glycoproteins; Mice; Mice, Nude; Monomeric GTP-Binding Proteins; Neoplasm Metastasis; Neoplasm Transplantation; Neoplasms, Experimental; NM23 Nucleoside Diphosphate Kinases; Nucleoside-Diphosphate Kinase; Ovarian Neoplasms; Oxides; Transcription Factors; Treatment Outcome; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2002 |
Radiofrequency ablation: Effect of pharmacologic modulation of hepatic and renal blood flow on coagulation diameter in a VX2 tumor model.
Topics: Adrenergic Agonists; Anesthetics, Inhalation; Animals; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Carcinoma; Catheter Ablation; Disease Models, Animal; Epinephrine; Halothane; Kidney; Kidney Neoplasms; Laser-Doppler Flowmetry; Liver; Liver Neoplasms; Oxides; Rabbits; Regional Blood Flow | 2004 |
Increased cellular glutathione and protection by bone marrow stromal cells account for the resistance of non-acute promylocytic leukemia acute myeloid leukemia cells to arsenic trioxide in vivo.
Topics: Acute Disease; Animals; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Bone Marrow Cells; Buthionine Sulfoximine; Cell Count; Cell Line, Tumor; Coculture Techniques; Disease Models, Animal; Drug Resistance, Neoplasm; Glutathione; Humans; Injections, Intraperitoneal; Leukemia, Myeloid; Mice; Mice, Inbred NOD; Mice, SCID; Oxides; Stromal Cells; Treatment Failure | 2006 |
[Experimental study of the anti-tumor effect of arsenic trioxide or thalidomide alone and combination of both for treatment of myelodysplastic syndrome model].
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Disease Models, Animal; Immunohistochemistry; Mice; Mice, Inbred BALB C; Mice, Nude; Mice, SCID; Myelodysplastic Syndromes; Neoplasm Transplantation; Oxides; Random Allocation; Survival Rate; Thalidomide; Tumor Cells, Cultured | 2006 |
Improved tumor destruction with arsenic trioxide and radiofrequency ablation in three animal models.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Blood Coagulation; Carcinoma, Renal Cell; Catheter Ablation; Cell Line, Tumor; Disease Models, Animal; Dose-Response Relationship, Drug; Growth Inhibitors; Humans; Laser-Doppler Flowmetry; Mice; Mice, Nude; Neoplasms, Experimental; Oxides; Rabbits; Rats; Rats, Inbred F344; Regional Blood Flow; Sarcoma | 2006 |
[Mechanisms of arsenic trioxide induced tumor cell apoptosis in myelodysplastic syndrome mice model in vivo].
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; Arsenic Trioxide; Arsenicals; Blotting, Western; Caspases; Disease Models, Animal; Electrophoretic Mobility Shift Assay; Humans; I-kappa B Proteins; Immunohistochemistry; Mice; Mice, Nude; Mice, SCID; Mitochondria; Myelodysplastic Syndromes; NF-kappa B; NF-KappaB Inhibitor alpha; Oxides; Reverse Transcriptase Polymerase Chain Reaction; Thalidomide | 2006 |
[Effect of early and non-early controlled-release of arsenic-trioxide eluting stents on restenosis inhibition in a canine model].
Topics: Angioplasty, Balloon, Coronary; Animals; Arsenic Trioxide; Arsenicals; Coronary Restenosis; Disease Models, Animal; Dogs; Drug-Eluting Stents; Oxides | 2007 |
A potentized homeopathic drug, Arsenicum Album 200, can ameliorate genotoxicity induced by repeated injections of arsenic trioxide in mice.
Topics: Animals; Antidotes; Arsenic Poisoning; Arsenic Trioxide; Arsenicals; Disease Models, Animal; Dose-Response Relationship, Drug; Homeopathy; Mice; Oxides; Random Allocation; Treatment Outcome; Water Pollutants, Chemical | 2007 |
[Effect of bortezomib used alone or in combination with arsenic trioxide on HL-60 cell xenograft in nude mice].
Topics: Animals; Apoptosis; Arsenic Trioxide; Arsenicals; Boronic Acids; Bortezomib; Cell Proliferation; Disease Models, Animal; HL-60 Cells; Humans; Leukemia; Male; Mice; Mice, Nude; Oxides; Pyrazines; Random Allocation; Xenograft Model Antitumor Assays | 2007 |
The delayed lung responses to single and repeated intratracheal administration of pure cobalt and hard metal powder in the rat.
Topics: Acetylglucosaminidase; Albumins; Animals; Arsenic Poisoning; Arsenic Trioxide; Arsenicals; Bronchoalveolar Lavage Fluid; Cobalt; Disease Models, Animal; Female; Fibronectins; Hyaluronic Acid; L-Lactate Dehydrogenase; Lung; Oxides; Powders; Proteins; Pulmonary Fibrosis; Rats; Rats, Sprague-Dawley; Silicon Dioxide; Staining and Labeling; Trachea; Tungsten Compounds | 1995 |
Efficacy of a potentized homoeopathic drug (Arsenicum Album-30) in reducing genotoxic effects produced by arsenic trioxide in mice: comparative studies of pre-, post- and combined pre- and post-oral administration and comparative efficacy of two microdose
Topics: Administration, Oral; Analysis of Variance; Animals; Antidotes; Antineoplastic Agents; Arsenic Poisoning; Arsenic Trioxide; Arsenicals; Chromosome Aberrations; Disease Models, Animal; Dose-Response Relationship, Drug; Homeopathy; Mice; Mitotic Index; Mutagenicity Tests; Oxides; Poisoning; Reference Values | 1999 |
Efficacy of a potentized homoeopathic drug (Arsenicum Album-30) in reducing genotoxic effects produced by arsenic trioxide in mice: II. Comparative efficacy of an antibiotic, actinomycin D alone and in combination with either of two microdoses.
Topics: Animals; Anti-Bacterial Agents; Arsenic Trioxide; Arsenicals; Chromosome Aberrations; Dactinomycin; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Interactions; Drug Therapy, Combination; Homeopathy; Male; Mice; Micronucleus Tests; Mitotic Index; Oxides; Random Allocation; Spermatozoa; Transcription, Genetic | 1999 |
Arsenic trioxide causes selective necrosis in solid murine tumors by vascular shutdown.
Topics: Animals; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Biological Transport; Disease Models, Animal; Fibrosarcoma; Male; Metabolic Clearance Rate; Methylcholanthrene; Mice; Mice, Inbred BALB C; Necrosis; Oxides; Perfusion | 1999 |
[Experimental study on combination of Ad-p53 with CDDP or As(2)O(3) in human lung adenocarcinoma cell line GLC-82].
Topics: Adenocarcinoma; Adenoviridae; Animals; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Cycle; Cisplatin; Combined Modality Therapy; Disease Models, Animal; Genetic Therapy; Mice; Mice, Nude; Neoplasm Transplantation; Neoplasms, Experimental; Oxides; Transfection; Transplants; Tumor Cells, Cultured; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays | 2000 |